Saller B, Clara R, Spöttl G, Siddle K, Mann K
Department of Internal Medicine II, Klinikum Grosshadern, University of Munich, F.R.G.
Clin Chem. 1990 Feb;36(2):234-9.
Human choriogonadotropin (hCG) and free hCG-beta values for 934 serum samples from patients with seminomatous or nonseminomatous testicular cancer were measured by highly specific immunoradiometric assays (IRMAS). In non-seminoma samples, hCG and hCG-beta were highly correlated (r = 0.82, P less than 0.001). Of 112 "marker-positive" seminoma samples, only 46 (41.1%) showed both increased hCG and hCG-beta. In 39 cases (34.8%) only hCG-beta and in 27 cases (24.1%) only dimer-hCG was increased. This makes the determination of hCG and hCG-beta, either by two assays or by a single hCG (+hCG-beta) assay, most reliable in these patients. For all samples, hCG (+hCG-beta) was measured by a polyclonal RIA and a monoclonal IRMA, which differed in their cross-reactivities with hCG-beta (234% and 720%, respectively). The hCG (+hCG-beta) IRMA, as a result of its higher hCG-beta cross-reactivity, was superior to the hCG (+hCG-beta) RIA in detecting slightly increased hCG-beta. Additionally, 11 widely used commercial hCG kits were tested for their hCG-beta cross-reactivities and showed values between less than 3% and 264%.
采用高特异性免疫放射分析（IRMA）法测定了934例精原细胞瘤或非精原细胞瘤睾丸癌患者血清样本中的人绒毛膜促性腺激素（hCG）和游离hCG-β值。在非精原细胞瘤样本中，hCG和hCG-β高度相关（r = 0.82，P＜0.001）。在112例“标志物阳性”的精原细胞瘤样本中，只有46例（41.1%）同时出现hCG和hCG-β升高。39例（34.8%）仅hCG-β升高，27例（24.1%）仅二聚体hCG升高。这使得通过两种检测方法或单一hCG（+hCG-β）检测方法测定hCG和hCG-β在这些患者中最为可靠。对于所有样本，hCG（+hCG-β）采用多克隆放射免疫分析（RIA）和单克隆免疫放射分析（IRMA）进行检测，这两种方法与hCG-β的交叉反应性不同（分别为234%和720%）。由于hCG（+hCG-β）IRMA对hCG-β的交叉反应性较高，在检测轻度升高的hCG-β方面优于hCG（+hCG-β）RIA。此外，还对11种广泛使用的商业hCG试剂盒进行了hCG-β交叉反应性测试，其值在不到3%至264%之间。
